Cobicistat (BioDeep_00000713327)
代谢物信息卡片
Cobicistat (GS-9350)
化学式: C40H53N7O5S2 (775.3549408)
中文名称: 可比司他
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5
InChI: InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1
描述信息
D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products
COVID info from Guide to PHARMACOLOGY
C471 - Enzyme Inhibitor
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
2 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:72291
- KEGGdrug: D09881
- PubChem: 25151504
- DrugBank: DB09065
- ChEMBL: CHEMBL2095208
- MeSH: Cobicistat
- CAS: 1004316-88-4
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Francesca Alberton, Laura Galli, Riccardo Lolatto, Caterina Candela, Nicola Gianotti, Matteo Chiurlo, Martina Ranzenigo, Martina Strano, Alessia Uglietti, Antonella Castagna. Outcome of Darunavir-Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure.
Drug design, development and therapy.
2024; 18(?):1153-1163. doi:
10.2147/dddt.s443775. [PMID: 38618279] - Sandra Rotea-Salvo, Víctor Giménez-Arufe, Alejandro Martínez-Pradeda, Carla Fernández-Oliveira, Álvaro Mena-de-Cea, Luis Margusino-Framiñán, Isabel Martín-Herranz, Purificación Cid-Silva. Lipid profile changes associated with antiretroviral therapies in a real-world cohort.
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.
2023 Sep; 47(5):T210-T217. doi:
10.1016/j.farma.2023.07.005. [PMID: 37673703] - Sandra Rotea-Salvo, Víctor Giménez-Arufe, Alejandro Martínez-Pradeda, Carla Fernández-Oliveira, Álvaro Mena-de-Cea, Luis Margusino-Framiñán, Isabel Martín-Herranz, Purificación Cid-Silva. Lipid profile changes associated with antiretroviral therapies in a real-world cohort.
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.
2023 Jun; ?(?):. doi:
10.1016/j.farma.2023.04.007. [PMID: 37349200] - Liqin Sun, Yun He, Liumei Xu, Fang Zhao, Yang Zhou, Lukun Zhang, Qiaoli Peng, Haitao Zhang, Qiuyue Zhang, Tingzhi Cao, Ying Song, Siyuan Wang, Man Rao, Xinyun Jia, Xiaoning Liu, Jing Zhou, Bin Ju, Hui Wang, Jiaye Liu. Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Journal of acquired immune deficiency syndromes (1999).
2022 10; 91(S1):S8-S15. doi:
10.1097/qai.0000000000003040. [PMID: 36094509] - Ruxandra-Cristina Marin, Adrian Streinu-Cercel, Lavinia Cristina Moleriu, Simona Gabriela Bungau. Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2022 Jun; 150(?):113077. doi:
10.1016/j.biopha.2022.113077. [PMID: 35658217] - Iart Luca Shytaj, Mohamed Fares, Lara Gallucci, Bojana Lucic, Mahmoud M Tolba, Liv Zimmermann, Julia M Adler, Na Xing, Judith Bushe, Achim D Gruber, Ina Ambiel, Ahmed Taha Ayoub, Mirko Cortese, Christopher J Neufeldt, Bettina Stolp, Mohamed Hossam Sobhy, Moustafa Fathy, Min Zhao, Vibor Laketa, Ricardo Sobhie Diaz, Richard E Sutton, Petr Chlanda, Steeve Boulant, Ralf Bartenschlager, Megan L Stanifer, Oliver T Fackler, Jakob Trimpert, Andrea Savarino, Marina Lusic. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters.
mBio.
2022 04; 13(2):e0370521. doi:
10.1128/mbio.03705-21. [PMID: 35229634] - Katy Moore, Nilay Thakkar, Mindy Magee, Heather Sevinsky, Blisse Vakkalagadda, Susan Lubin, Cyril Llamoso, Peter Ackerman. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
Antimicrobial agents and chemotherapy.
2022 04; 66(4):e0225121. doi:
10.1128/aac.02251-21. [PMID: 35315687] - Jeremiah D Momper, Jiajia Wang, Alice Stek, David E Shapiro, Kathleen M Powis, Mary E Paul, Martina L Badell, Renee Browning, Nahida Chakhtoura, Kayla Denson, Kittipong Rungruengthanakit, Kathleen George, Edmund V Capparelli, Mark Mirochnick, Brookie M Best. Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV.
Journal of acquired immune deficiency syndromes (1999).
2022 03; 89(3):303-309. doi:
10.1097/qai.0000000000002856. [PMID: 34732682] - Eman Zeyad I Elmekaty, Rim Alibrahim, Rania Hassanin, Sitelbanat Eltaib, Ahmed Elsayed, Fatima Rustom, Mohamed Izham Mohamed Ibrahim, Mohammed Abu Khattab, Hussam Al Soub, Muna Al Maslamani, Abdullatif Al-Khal. Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study.
PloS one.
2022; 17(5):e0267884. doi:
10.1371/journal.pone.0267884. [PMID: 35507606] - José Moltó, Lucía Bailón, Clara Pérez-Mañá, Ester Papaseit, Cristina Miranda, Soraya Martín, Beatriz Mothe, Magí Farré. Absence of drug-drug interactions between γ-hydroxybutyric acid (GHB) and cobicistat.
The Journal of antimicrobial chemotherapy.
2021 12; 77(1):181-184. doi:
10.1093/jac/dkab359. [PMID: 34561695] - Engie Salama, Lucas Hill, Nimish Patel, Brookie M Best, Jeremiah D Momper. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
Journal of acquired immune deficiency syndromes (1999).
2021 12; 88(4):389-392. doi:
10.1097/qai.0000000000002765. [PMID: 34285156] - Huan Xia, Xiao-Jie Huang, Yue Hu, Li-Ying Gao, Yue Wu, Hao Wu, Zhong-Fang Yan, Ping Ma. Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
Chinese medical journal.
2021 Oct; 134(23):2850-2856. doi:
10.1097/cm9.0000000000001824. [PMID: 34653085] - Margherita Bracchi, Nicole Pagani, Alessia Dalla Pria, Ana Milinkovic, Nneka Nwokolo, Lervina Thomas, Sundhyia Mandalia, Marta Boffito, Graeme Moyle. A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.
HIV research & clinical practice.
2021 10; 22(5):128-139. doi:
. [PMID: 34551678] - Chih-Cheng Lai, Chien-Ming Chao, Po-Ren Hsueh. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
2021 Oct; 54(5):767-775. doi:
10.1016/j.jmii.2021.05.011. [PMID: 34253490] - Luigi Cavanna, Gabriele Cremona, Chiara Citterio, Camilla Di Nunzio, Monica Muroni, Anna Maria Andena, Evelina Cattadori, Mirella Gubbelini, Lara Muroni, Roberta Schiavo, Massimo Nolli, Mauro Codeluppi, Pietro Maniscalco, Guido Pedrazzini. COVID-19 Outbreak in Italy: Report on the First 124 Consecutive Patients Treated at Home.
The Tohoku journal of experimental medicine.
2021 09; 255(1):61-69. doi:
10.1620/tjem.255.61. [PMID: 34588347] - Richard E Haaland, Jeffrey Fountain, Chuong Dinh, L Davis Lupo, Amy Martin, Christopher Conway-Washington, LaShonda Hall, Colleen F Kelley, J Gerardo Garcia-Lerma, Walid Heneine. Antiretroviral drug exposure in urethral and glans surface sampling of the penis.
The Journal of antimicrobial chemotherapy.
2021 08; 76(9):2368-2374. doi:
10.1093/jac/dkab155. [PMID: 34007982] - Hideaki Okochi, Alexander Louie, Nhi Phung, Kevin Zhang, Regina M Tallerico, Karen Kuncze, Matthew A Spinelli, Catherine A Koss, Leslie Z Benet, Monica Gandhi. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
Drug testing and analysis.
2021 Jul; 13(7):1354-1370. doi:
10.1002/dta.3033. [PMID: 33742745] - Jeremiah D Momper, Jiajia Wang, Alice Stek, David E Shapiro, Gwendolyn B Scott, Mary E Paul, Irma L Febo, Sandra Burchett, Elizabeth Smith, Nahida Chakhtoura, Kayla Denson, Kittipong Rungruengthanakit, Kathleen George, Derek Z Yang, Edmund V Capparelli, Mark Mirochnick, Brookie M Best. Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV.
AIDS (London, England).
2021 07; 35(8):1191-1199. doi:
10.1097/qad.0000000000002857. [PMID: 34076612] - Oliver Ackaert, David McDougall, Carlos Pérez-Ruixo, Juan Jose Pérez-Ruixo, John Jezorwski, Herta M Crauwels. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
The AAPS journal.
2021 06; 23(4):82. doi:
10.1208/s12248-021-00607-8. [PMID: 34100149] - Uraiwan Akanit, Shahab Bozorgmehri, Kawther Alquadan, Joelle Nelson, Bruce Kaplan, Tezcan Ozrazgat-Baslanti, Karl L Womer. Improved ability to achieve target trough levels with liquid versus capsule tacrolimus in kidney transplant patients with HIV on protease inhibitor- or cobicistat-based regimens.
Transplant infectious disease : an official journal of the Transplantation Society.
2021 Jun; 23(3):e13517. doi:
10.1111/tid.13517. [PMID: 33217091] - Fehmi Tabak, Esra Zerdali, Ozlem Altuntaş, Alper Gunduz, Sibel Bolukcu, Bilgul Mete, Inci Y Nakir, Hayat Kumbasar Karaosmanoglu, Dilek S Yildiz, Meliha Meric Koc, İlyas Dokmetas. Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data.
International journal of STD & AIDS.
2021 05; 32(6):562-569. doi:
10.1177/0956462420983692. [PMID: 33599173] - Mizuki Kobayashi, Miria Chinen, Atsushi Hirano, Tsunefusa Hayashida, Koji Watanabe, Junichi Masuda. Successful treatment by doravirine with cobicistat-boosted darunavir for end-stage renal failure under chronic haemodialysis.
The Journal of antimicrobial chemotherapy.
2021 04; 76(5):1370-1372. doi:
10.1093/jac/dkab001. [PMID: 33491079] - Yu-Shan Huang, Chien-Yu Cheng, Bo-Huang Liou, Po-Liang Lu, Shu-Hsing Cheng, Yuan-Ti Lee, Chun-Eng Liu, Hsin-Yun Sun, Chia-Jui Yang, Hung-Jen Tang, Shih-Ping Lin, Mao-Wang Ho, Sung-Hsi Huang, Hung-Chin Tsai, Chen-Hsiang Lee, Chien-Ching Hung. Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.
Journal of acquired immune deficiency syndromes (1999).
2021 04; 86(4):473-481. doi:
10.1097/qai.0000000000002589. [PMID: 33273214] - Jovana Milic, Alessio Novella, Marianna Meschiari, Marianna Menozzi, Antonella Santoro, Andrea Bedini, Gianluca Cuomo, Erica Franceschini, Margherita Digaetano, Federica Carli, Giacomo Ciusa, Sara Volpi, Erica Bacca, Giacomo Franceschi, Dina Yaacoub, Carlotta Rogati, Marco Tutone, Giulia Burastero, Matteo Faltoni, Vittorio Iadisernia, Giovanni Dolci, Andrea Cossarizza, Cristina Mussini, Luca Pasina, Giovanni Guaraldi. Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia.
AIDS research and human retroviruses.
2021 04; 37(4):283-291. doi:
10.1089/aid.2020.0305. [PMID: 33619997] - Nicolas Hohmann, Farastuk Bozorgmehr, Petros Christopoulos, Gerd Mikus, Antje Blank, Jürgen Burhenne, Michael Thomas, Walter E Haefeli. Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.
Clinical and translational science.
2021 03; 14(2):487-491. doi:
10.1111/cts.12921. [PMID: 33222380] - Karthik Lingineni, Nashid Farhan, Sarah Kim, Rodrigo Cristofoletti, Lori A Gordon, Parag Kumar, Scott Penzak, Colleen Hadigan, Jomy M George, Joshua D Brown, Stephan Schmidt. Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment.
Clinical pharmacology and therapeutics.
2021 01; 109(1):193-200. doi:
10.1002/cpt.2087. [PMID: 33073366] - Shaojia Lu, Ning Wei, Jiajun Jiang, Lingling Wu, Jifang Sheng, Jianying Zhou, Qiang Fang, Yu Chen, Shufa Zheng, Feng Chen, Tingbo Liang, Shaohua Hu. First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.
Journal of affective disorders.
2020 12; 277(?):337-340. doi:
10.1016/j.jad.2020.08.031. [PMID: 32858315] - Palumbo Roberto, Londrino Francesco, Cordova Emanuela, Gambardella Giorgia, Niscola Pasquale, Dominijanni Sara. Current treatment of COVID-19 in renal patients: hope or hype?.
Internal and emergency medicine.
2020 11; 15(8):1389-1398. doi:
10.1007/s11739-020-02510-0. [PMID: 32986137] - Antonio Desai, Orazio Giuseppe Santonocito, Giuseppe Caltagirone, Maria Kogan, Federica Ghetti, Ilaria Donadoni, Francesca Porro, Victor Savevski, Dario Poretti, Michele Ciccarelli, Filippo Martinelli Boneschi, Antonio Voza. Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical Investigation.
Medicina (Kaunas, Lithuania).
2020 Oct; 56(11):. doi:
10.3390/medicina56110572. [PMID: 33138045] - Guan-Jhou Chen, Yu-Lin Lee, Chen-Hsiang Lee, Hsin-Yun Sun, Chien-Yu Cheng, Hung-Chin Tsai, Sung-Hsi Huang, Yi-Chieh Lee, Min-Han Hsieh, Sui-Yuan Chang, Yu-Chung Chuang, Li-Shin Su, Sui-Fang Chang, Hung-Jen Tang, Chien-Ching Hung. Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV.
The Journal of antimicrobial chemotherapy.
2020 10; 75(10):2986-2993. doi:
10.1093/jac/dkaa287. [PMID: 32737511] - Eun Jin Kim, Sun Ha Choi, Jae Seok Park, Yong Shik Kwon, Jaehee Lee, Yeonjae Kim, Shin Yup Lee, Eun Young Choi. Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection.
Yonsei medical journal.
2020 Sep; 61(9):826-830. doi:
10.3349/ymj.2020.61.9.826. [PMID: 32882767] - Giulio Guagliumi, Aurelio Sonzogni, Irene Pescetelli, Dario Pellegrini, Aloke V Finn. Microthrombi and ST-Segment-Elevation Myocardial Infarction in COVID-19.
Circulation.
2020 08; 142(8):804-809. doi:
10.1161/circulationaha.120.049294. [PMID: 32677840] - Marilù Bartiromo, Beatrice Borchi, Annarita Botta, Alfredo Bagalà, Gianmarco Lugli, Marta Tilli, Annalisa Cavallo, Brunilda Xhaferi, Roberta Cutruzzulà, Augusto Vaglio, Silvia Bresci, Aida Larti, Alessandro Bartoloni, Calogero Cirami. Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Transplant infectious disease : an official journal of the Transplantation Society.
2020 Aug; 22(4):e13286. doi:
10.1111/tid.13286. [PMID: 32279418] - Andrea Gori, Andrea Antinori, Alessandra Vergori, Maria Vittoria Cossu, Barbara Menzaghi, Gaetana Sterrantino, Stefano Rusconi, Anna Maria Cattelan, Francesco Castelli, Nicola Gianotti, Giancarlo Orofino, Diego Ripamonti, Stefano Savinelli, Elio Manzillo, Teresa Antonia Santantonio, Benedetto Maurizio Celesia, Roberto Cauda, Renato Maserati, Antonella d'Arminio Monforte, Christof Stingone, Stefano Bonora, Alessia Uglietti, Roberta Termini, Francesco Rucci, Daniela Mancusi. Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The 'STORE' Study.
Journal of acquired immune deficiency syndromes (1999).
2020 07; 84(3):290-294. doi:
10.1097/qai.0000000000002331. [PMID: 32101882] - Elisa Maria Stroppa, Ilaria Toscani, Chiara Citterio, Elisa Anselmi, Elena Zaffignani, Mauro Codeluppi, Luigi Cavanna. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).
Future oncology (London, England).
2020 Jul; 16(20):1425-1432. doi:
10.2217/fon-2020-0369. [PMID: 32403946] - Ilaria Gandolfini, Marco Delsante, Enrico Fiaccadori, Gianluigi Zaza, Lucio Manenti, Anna Degli Antoni, Licia Peruzzi, Leonardo V Riella, Paolo Cravedi, Umberto Maggiore. COVID-19 in kidney transplant recipients.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
2020 Jul; 20(7):1941-1943. doi:
10.1111/ajt.15891. [PMID: 32233067] - Chen Chen, Moxian Chen, Cong Cheng, Yun Chi, Zhiliang Hu, Yuan Liu, Shan Huang, Yanling Lv, Chongfeng Liang, Damin Jiao, Yongxiang Yi, Xia Zhang, Wenkui Sun, Hongxia Wei. A special symptom of olfactory dysfunction in coronavirus disease 2019: report of three cases.
Journal of neurovirology.
2020 06; 26(3):456-458. doi:
10.1007/s13365-020-00849-w. [PMID: 32424616] - F Maggiolo, N Gianotti, L Comi, E Di Filippo, L Fumagalli, S Nozza, L Galli, D Valenti, M Rizzi, A Castagna. Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2).
The Journal of antimicrobial chemotherapy.
2020 05; 75(5):1332-1337. doi:
10.1093/jac/dkaa018. [PMID: 32129855] - Yongtao Duan, Hai-Liang Zhu, Chongchen Zhou. Advance of promising targets and agents against COVID-19 in China.
Drug discovery today.
2020 05; 25(5):810-812. doi:
10.1016/j.drudis.2020.02.011. [PMID: 32198066] - Valentina Spezzani, Alessio Piunno, Hans-Ulrich Iselin. Benign COVID-19 in an immunocompromised cancer patient - the case of a married couple.
Swiss medical weekly.
2020 04; 150(?):w20246. doi:
10.4414/smw.2020.20246. [PMID: 32277836] - Chloe Orkin, Joseph J Eron, Jürgen Rockstroh, Daniel Podzamczer, Stefan Esser, Linos Vandekerckhove, Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, John Jezorwski, Magda Opsomer. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
AIDS (London, England).
2020 04; 34(5):707-718. doi:
10.1097/qad.0000000000002463. [PMID: 31833849] - Hélène Gouget, Gaëlle Noé, Aurélie Barrail-Tran, Valérie Furlan. UPLC-MS/MS method for the simultaneous quantification of bictegravir and 13 others antiretroviral drugs plus cobicistat and ritonavir boosters in human plasma.
Journal of pharmaceutical and biomedical analysis.
2020 Mar; 181(?):113057. doi:
10.1016/j.jpba.2019.113057. [PMID: 31962247] - Po-Hsien Kuo, Hsin-Yun Sun, Yu-Chung Chuang, Pei-Ying Wu, Wen-Chun Liu, Chien-Ching Hung. Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2020 Mar; 92(?):71-77. doi:
10.1016/j.ijid.2019.12.029. [PMID: 31884172] - Laurence Brunet, Christina Wyatt, Ricky Hsu, Karam Mounzer, Jennifer Fusco, Gregory Fusco. Assessing bias introduced in estimated glomerular filtration rate by the inhibition of creatinine tubular secretion from common antiretrovirals.
Antiviral therapy.
2020; 25(5):287-292. doi:
10.3851/imp3373. [PMID: 33211670] - Frank A Post, Lisa Hamzah. Correcting eGFR for the effects of ART on tubular creatinine secretion: does one size fit all?.
Antiviral therapy.
2020; 25(5):241-243. doi:
10.3851/imp3378. [PMID: 33459634] - Richard E Haaland, Amy Martin, Tamee Livermont, Jeffrey Fountain, Chuong Dinh, Angela Holder, Lindsey D Lupo, LaShonda Hall, Christopher Conway-Washington, Colleen F Kelley. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Journal of acquired immune deficiency syndromes (1999).
2019 11; 82(3):252-256. doi:
10.1097/qai.0000000000002133. [PMID: 31335590] - Hwa-Ping Feng, Zifang Guo, Christine Fandozzi, Deborah Panebianco, Luzelena Caro, Dennis Wolford, Daniel P Dreyer, Robert Valesky, Monika Martinho, Matthew L Rizk, Marian Iwamoto, Wendy W Yeh. Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants.
Clinical pharmacology in drug development.
2019 10; 8(7):952-961. doi:
10.1002/cpdd.702. [PMID: 31173673] - Arkaitz Imaz, Jordi Niubó, Mackenzie L Cottrell, Emilia Perez, Angela D M Kashuba, Juan M Tiraboschi, Sandra Morenilla, Benito Garcia, Daniel Podzamczer. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2019 09; 69(8):1403-1409. doi:
10.1093/cid/ciy1074. [PMID: 30561517] - Ryota Kikuchi, William J Chiou, Miriam A Kasai, Sonia M de Morais, Daniel A J Bow. No Inhibition of MATE1/2K-Mediated Renal Creatinine Secretion Predicted With Ritonavir or Cobicistat.
Journal of pharmaceutical sciences.
2019 09; 108(9):3118-3123. doi:
10.1016/j.xphs.2019.04.023. [PMID: 31034908] - Lucia Taramasso, Elena Ricci, Antonio Cascio, Laura Valsecchi, Barbara Menzaghi, Nicola Squillace, Paolo Maggi, Giuseppe Vittorio De Socio, Chiara Dentone, Giordano Madeddu, Giovanni F Pellicanò, Leonardo Calza, Goffredo Angioni, Paolo Bonfanti, Antonio Di Biagio. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA).
AIDS research and therapy.
2019 08; 16(1):21. doi:
10.1186/s12981-019-0236-0. [PMID: 31451115] - José R Santos, Adrian Curran, Jordi Navarro-Mercade, Mario F Ampuero, Pablo Pelaez, Nuria Pérez-Alvarez, Bonaventura Clotet, Roger Paredes, José Moltó. Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice.
AIDS research and human retroviruses.
2019 06; 35(6):513-518. doi:
10.1089/aid.2018.0178. [PMID: 30909716] - H M Crauwels, O Osiyemi, C Zorrilla, C Bicer, K Brown. Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen.
HIV medicine.
2019 05; 20(5):337-343. doi:
10.1111/hiv.12721. [PMID: 30873741] - Kimberley Brown, David Thomas, Kevin McKenney, Michael Reeder, Richard Bruce Simonson, Ceyhun Bicer, Richard E Nettles, Herta Crauwels. Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen.
Clinical pharmacology in drug development.
2019 05; 8(4):541-548. doi:
10.1002/cpdd.632. [PMID: 30508308] - Antonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Antonio Di Biagio, Giulia Marchetti, Sergio Lo Caputo, Stefano Rusconi, Nicola Gianotti, Valentina Mazzotta, Giovanni Mazzarello, Andrea Costantini, Antonella Castagna, Andrea Antinori. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
The Journal of antimicrobial chemotherapy.
2019 05; 74(5):1363-1367. doi:
10.1093/jac/dky566. [PMID: 30698801] - Bart G J Dekkers, Wouter F W Bierman, Daan J Touw, Jan-Willem C Alffenaar. Relevance of the drug-drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat.
AIDS (London, England).
2019 05; 33(6):1100-1102. doi:
10.1097/qad.0000000000002162. [PMID: 30946167] - J M Llibre, A Montoliu, J M Miró, P Domingo, M Riera, J Tiraboschi, A Curran, F Homar, J Ambrosioni, N Abdulghani, L Force, J Peraire, J Casabona. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
HIV medicine.
2019 03; 20(3):237-247. doi:
10.1111/hiv.12710. [PMID: 30688007] - Rita Godinho, Serge Bugnon, Terezija Gracin, James Tataw. Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya® (EVG/COBI/FTC/TAF) and simvastatin; a case report.
BMC nephrology.
2019 02; 20(1):69. doi:
10.1186/s12882-019-1257-6. [PMID: 30808332] - G Baldin, A Ciccullo, A Capetti, S Rusconi, G Sterrantino, M V Cossu, A Giacomelli, F Lagi, A Latini, P Bagella, A De Luca, S Di Giambenedetto, G Madeddu. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
HIV medicine.
2019 02; 20(2):164-168. doi:
10.1111/hiv.12688. [PMID: 30457197] - Sophia R Majeed, Steve West, Kah Hiing Ling, Moupali Das, Brian P Kearney. Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
Antiviral therapy.
2019; 24(8):557-566. doi:
10.3851/imp3343. [PMID: 31933482] - Jeremiah D Momper, Brookie M Best, Jiajia Wang, Edmund V Capparelli, Alice Stek, Emily Barr, Martina L Badell, Edward P Acosta, Murli Purswani, Elizabeth Smith, Nahida Chakhtoura, Kyunghun Park, Sandra Burchett, David E Shapiro, Mark Mirochnick. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.
AIDS (London, England).
2018 11; 32(17):2507-2516. doi:
10.1097/qad.0000000000001992. [PMID: 30134297] - Nadia Galizzi, Laura Galli, Andrea Poli, Vincenzo Spagnuolo, Antonella Castagna, Nicola Gianotti. Glomerular filtration rate estimated by cystatin C formulas in HIV-1 patients treated with dolutegravir, rilpivirine or cobicistat.
The new microbiologica.
2018 10; 41(4):256-261. doi:
NULL. [PMID: 30252923] - Álvaro Mena, Purificación Cid, Carlos Dueñas, María Ángeles Garcinuño, Juan Francisco Lorenzo, Luis Margusino, Marina Quiñones, Carmen Grande, Iria Rodríguez-Osorio, Ángeles Castro. Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy.
HIV clinical trials.
2018 10; 19(5):197-201. doi:
10.1080/15284336.2018.1513974. [PMID: 30605006] - Takuma Yonemura, Nozomi Okada, Koichi Sagane, Kazuhiro Okamiya, Hideki Ozaki, Toshiaki Iida, Hiroyuki Yamada, Hiroki Yagura. Effects of Milk or Apple Juice Ingestion on the Pharmacokinetics of Elvitegravir and Cobicistat in Healthy Japanese Male Volunteers: A Randomized, Single-Dose, Three-Way Crossover Study.
Clinical pharmacology in drug development.
2018 09; 7(7):737-743. doi:
10.1002/cpdd.425. [PMID: 29364579] - Sara Algeelani, Novera Alam, Md Amin Hossain, Gerd Mikus, David J Greenblatt. In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.
Xenobiotica; the fate of foreign compounds in biological systems.
2018 Aug; 48(8):764-769. doi:
10.1080/00498254.2017.1370655. [PMID: 28891378] - Andrew J Ocque, Colleen E Hagler, Gene D Morse, Scott L Letendre, Qing Ma. Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid.
Journal of pharmaceutical and biomedical analysis.
2018 Jul; 156(?):163-169. doi:
10.1016/j.jpba.2018.04.035. [PMID: 29709783] - Yan Xin, Winnie Weng, Bernard P Murray, Eugene J Eisenberg, Jason W Chien, John Ling, Jeffrey A Silverman. The Drug-Drug Interaction Profile of Presatovir.
Journal of clinical pharmacology.
2018 06; 58(6):771-780. doi:
10.1002/jcph.1073. [PMID: 29412463] - Sally Hodder, Kathleen Squires, Cissy Kityo, Debbie Hagins, Anchalee Avihingsanon, Anna Kido, Shuping Jiang, Rima Kulkarni, Andrew Cheng, Huyen Cao. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Journal of acquired immune deficiency syndromes (1999).
2018 06; 78(2):209-213. doi:
10.1097/qai.0000000000001663. [PMID: 29481486] - Eugènia Negredo, Bonaventura Clotet. Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
Expert opinion on pharmacotherapy.
2018 Jun; 19(8):929-934. doi:
10.1080/14656566.2018.1472766. [PMID: 29767543] - Edwin DeJesus, Bernard Haas, Sorana Segal-Maurer, Moti N Ramgopal, Anthony Mills, Nicolas Margot, Ya-Pei Liu, Tariro Makadzange, Scott McCallister. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
AIDS research and human retroviruses.
2018 04; 34(4):337-342. doi:
10.1089/aid.2017.0203. [PMID: 29368537] - José Moltó, Adrian Curran, Cristina Miranda, Elizabeth Challenger, José Ramón Santos, Esteban Ribera, Saye Khoo, Marta Valle, Bonaventura Clotet. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
The Journal of antimicrobial chemotherapy.
2018 03; 73(3):732-737. doi:
10.1093/jac/dkx459. [PMID: 29237008] - Alicia Gutierrez-Valencia, Maria Trujillo-Rodriguez, Tamara Fernandez-Magdaleno, Nuria Espinosa, Pompeyo Viciana, Luis F López-Cortés. Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations.
Journal of the International AIDS Society.
2018 02; 21(2):. doi:
10.1002/jia2.25072. [PMID: 29430854] - Nicola Squillace, Giorgio Bozzi, Elisa Colella, Andrea Gori, Alessandra Bandera. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Drug design, development and therapy.
2018; 12(?):3635-3643. doi:
10.2147/dddt.s147493. [PMID: 30464395] - Miguel A López-Ruz, Miguel A López-Zúñiga, María Carmen Gonzalvo, Antonio Sampedro, Juan Pasquau, Carmen Hidalgo, Javier Rosario, Jose Antonio Castilla. Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients.
PloS one.
2018; 13(4):e0196257. doi:
10.1371/journal.pone.0196257. [PMID: 29689065] - Dario Cattaneo, Davide Minisci, Sara Baldelli, Cristina Mazzali, Andrea Giacomelli, Laura Milazzo, Paola Meraviglia, Chiara Resnati, Giuliano Rizzardini, Emilio Clementi, Massimo Galli, Cristina Gervasoni. Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
Journal of acquired immune deficiency syndromes (1999).
2018 01; 77(1):86-92. doi:
10.1097/qai.0000000000001558. [PMID: 28961682] - Josep M Llibre, Hortensia Álvarez, Miguel Yzusqui. Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review.
AIDS reviews.
2018; 20(3):158-170. doi:
10.24875/aidsrev.18000006. [PMID: 30264825] - Catia Marzolini, Laurent Decosterd, Ursula Winterfeld, Frédéric Tissot, Katyuska Francini, Thierry Buclin, Françoise Livio. Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report.
British journal of clinical pharmacology.
2017 12; 83(12):2835-2838. doi:
10.1111/bcp.13310. [PMID: 28512794] - Marianne Harris, Bruce Ganase, Birgit Watson, P Richard Harrigan, Julio S G Montaner, Mark W Hull. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
AIDS research and therapy.
2017 Nov; 14(1):59. doi:
10.1186/s12981-017-0185-4. [PMID: 29096670] - P Echeverría, A Bonjoch, J Puig, A Ornella, B Clotet, E Negredo. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia.
HIV medicine.
2017 11; 18(10):782-786. doi:
10.1111/hiv.12530. [PMID: 28671337] - Parag Kumar, Lori A Gordon, Kristina M Brooks, Jomy M George, Anela Kellogg, Maryellen McManus, Raul M Alfaro, Khanh Nghiem, Jay Lozier, Colleen Hadigan, Scott R Penzak. Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.
Antimicrobial agents and chemotherapy.
2017 11; 61(11):. doi:
10.1128/aac.01201-17. [PMID: 28848011] - Hanni Bartels, Laurent Decosterd, Manuel Battegay, Catia Marzolini. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
The Journal of antimicrobial chemotherapy.
2017 09; 72(9):2574-2577. doi:
10.1093/jac/dkx165. [PMID: 28575323] - Floor J E Lubberman, Nielka P van Erp, Rob Ter Heine, Carla M L van Herpen. Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal.
Acta oncologica (Stockholm, Sweden).
2017 09; 56(9):1238-1240. doi:
10.1080/0284186x.2017.1311024. [PMID: 28388255] - Emilie R Elliot, Alieu Amara, Nicole Pagani, Laura Else, Graeme Moyle, Alex Schoolmeesters, Chris Higgs, Saye Khoo, Marta Boffito. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
The Journal of antimicrobial chemotherapy.
2017 07; 72(7):2035-2041. doi:
10.1093/jac/dkx108. [PMID: 28407075] - Marine Perrier, Charlotte Charpentier, Gilles Peytavin, Minh Lê, Louis Blondel, Benoit Visseaux, Véronique Joly, Adriana Pinto, Sophie Matheron, Yazdan Yazdanpanah, Diane Descamps, Roland Landman. Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
The Journal of antimicrobial chemotherapy.
2017 06; 72(6):1745-1751. doi:
10.1093/jac/dkx018. [PMID: 28186251] - Francisco Antunes. Atazanavir sulfate + cobicistat for the treatment of HIV infection.
Expert review of anti-infective therapy.
2017 06; 15(6):569-576. doi:
10.1080/14787210.2017.1323634. [PMID: 28443391] - Marco Simiele, Alessandra Ariaudo, Amedeo De Nicolò, Fabio Favata, Martina Ferrante, Chiara Carcieri, Stefano Bonora, Giovanni Di Perri, Antonio De Avolio. UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.
Journal of pharmaceutical and biomedical analysis.
2017 May; 138(?):223-230. doi:
10.1016/j.jpba.2017.02.002. [PMID: 28219799] - Arkaitz Imaz, Daniel Podzamczer. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Expert review of anti-infective therapy.
2017 03; 15(3):195-209. doi:
10.1080/14787210.2017.1286736. [PMID: 28117606] - James Milburn, Rachael Jones, Jeremy B Levy. Renal effects of novel antiretroviral drugs.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2017 03; 32(3):434-439. doi:
10.1093/ndt/gfw064. [PMID: 27190354] - Nicola Squillace, Elena Ricci, Tiziana Quirino, Andrea Gori, Alessandra Bandera, Laura Carenzi, Giuseppe Vittorio De Socio, Giancarlo Orofino, Canio Martinelli, Giordano Madeddu, Stefano Rusconi, Paolo Maggi, Benedetto Maurizio Celesia, Laura Cordier, Francesca Vichi, Leonardo Calza, Katia Falasca, Antonio Di Biagio, Giovanni Francesco Pellicanò, Paolo Bonfanti. Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
PloS one.
2017; 12(6):e0179254. doi:
10.1371/journal.pone.0179254. [PMID: 28632758] - L Yunquera-Romero, R Asensi-Díez, J C Del Rio-Valencia, I Muñoz-Castillo, M A Castaño-Carracedo. [Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.
2016 Dec; 29(6):308-317. doi:
NULL. [PMID: 27888600] - Aditya H Gaur, Hilda Kizito, Wasana Prasitsueubsai, Natella Rakhmanina, Mohammed Rassool, Rana Chakraborty, Jagmohan Batra, Pope Kosalaraksa, Wicharn Luesomboon, Danielle Porter, Yongwu Shao, Michael Myers, Lillian Ting, Devi SenGupta, Erin Quirk, Martin S Rhee. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
The lancet. HIV.
2016 12; 3(12):e561-e568. doi:
10.1016/s2352-3018(16)30121-7. [PMID: 27765666] - Kathleen Squires, Cissy Kityo, Sally Hodder, Margaret Johnson, Evgeny Voronin, Debbie Hagins, Anchalee Avihingsanon, Ellen Koenig, Shuping Jiang, Kirsten White, Andrew Cheng, Javier Szwarcberg, Huyen Cao. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
The lancet. HIV.
2016 09; 3(9):e410-e420. doi:
10.1016/s2352-3018(16)30016-9. [PMID: 27562742] - Sujan Dilly Penchala, Sandra Fawcett, Laura Else, Deirdre Egan, Alieu Amara, Emilie Elliot, Elizabeth Challenger, David Back, Marta Boffito, Saye Khoo. The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 Aug; 1027(?):174-80. doi:
10.1016/j.jchromb.2016.05.040. [PMID: 27290668] - Catia Marzolini, Sara Gibbons, Saye Khoo, David Back. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
The Journal of antimicrobial chemotherapy.
2016 07; 71(7):1755-8. doi:
10.1093/jac/dkw032. [PMID: 26945713] - Catalina Barceló, Frédéric Gaspar, Manel Aouri, Alice Panchaud, Margalida Rotger, Monia Guidi, Matthias Cavassini, Thierry Buclin, Laurent A Decosterd, Chantal Csajka. Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
The Journal of antimicrobial chemotherapy.
2016 07; 71(7):1933-42. doi:
10.1093/jac/dkw050. [PMID: 27029846] - Sarah L Greig, Emma D Deeks. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Drugs.
2016 Jun; 76(9):957-68. doi:
10.1007/s40265-016-0586-z. [PMID: 27189707] - Thai Nguyen, Ian McNicholl, Joseph M Custodio, Javier Szwarcberg, David Piontkowsky. Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir.
AIDS reviews.
2016 Apr; 18(2):101-11. doi:
. [PMID: 27196356] - Stein Schalkwijk, Angela Colbers, Deborah Konopnicki, Rick Greupink, Frans G M Russel, David Burger. First reported use of elvitegravir and cobicistat during pregnancy.
AIDS (London, England).
2016 Mar; 30(5):807-8. doi:
10.1097/qad.0000000000000976. [PMID: 26913711] - Nicolas A Margot, Kathryn M Kitrinos, Marshall Fordyce, Scott McCallister, Michael D Miller, Christian Callebaut. Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
HIV clinical trials.
2016 Mar; 17(2):78-87. doi:
10.1080/15284336.2016.1142731. [PMID: 26892863] - Pengcheng Wang, Amina I Shehu, Ke Liu, Jie Lu, Xiaochao Ma. Biotransformation of Cobicistat: Metabolic Pathways and Enzymes.
Drug metabolism letters.
2016; 10(2):111-23. doi:
10.2174/1872312810666160303112212. [PMID: 26935921]